Recd PCT/PPO 06 JUN 2002 CKET NO. BM45413

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thonnard Serial No.: 10/088,125

I.A. Filing Date: 14 September 2000

For: Novel Compounds BASB128

Group Art Unit No.: Unknown

Examiner: Unknown

BOX PCT

Commissioner for Patents Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: **BOX PCT**, Commissioner for Patents, Washington, D.C. 20231, on 5-39-03.

By: Susan C. Sheehan

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Applicants herein make available to the Patent and Trademark Office copies of the documents:

- ☐ listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
- listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:

Serial No.

Serial No.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion

ę, .

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

This Information Disclosure Statement is being filed:

(1)

	within three months of the filing date of the patent application.							
	within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.							
\boxtimes	before the mailing date of a first Office Action on the merits.							
	after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:							
	the Statement under 37 CFR 1.97(e) (see "Statement" below);							
or								
	the Fee of \$180.00 set forth in 37 CFR 1.17(p); or							
	No fee is owed by the applicants.							
	after the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).							
(2) Statem	nent							
	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.							
(If this box is checked, do not check any further Statement boxes.)								
or								
	The person signing immediately below hereby states that no item information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designation 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.							

		The p	erson making the statement is:			
			the inventor(s) who sign(s) below:			
			Signature of the Inventor(s)			
			Typed or Printed Name of the Inventor(s)			
			or			
			a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:			
			Signature of the Person(s)			
			Typed or Printed Name of the Person			
			Address of Person Signing			
			or			
			the undersigned attorney who signs on the basis of the information:			
			supplied by the inventor(s).			
			supplied by an individual designated in 37 CFR 1.56(c).			
			in the attorney's file.			
			Signature of the attorney			
(3)	Petit	ion				
			Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. (This box checked only if a Final Office Action has issued)			
	(4)	Fees				
		\boxtimes	No Fee is owed by the applicants.			
			The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.			
			The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.			

(5)	Method of Payment of Fees			
		Attached is a check in the amount of \$180.00.		
		Charge Account No. 50-0258 in the amount of \$ 180.00. (A duplicate of this request is attached).		
(6)	Authorization to Charge Additional Fees			
	\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 50-0258.		
(7)	Instructions as to Overpayment			
	\boxtimes	Please credit Account No. 50-0258 for any overpayment.		
		Please refund Dechert Price & Rhoads in the amount of \$		
	1.0 1	1		

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Arthur E. Jackson Registration No. 34,354 Attorney for Applicants

DECHERT 1717 Arch Street 4000 Bell Atlantic Tower Philadelphia, PA 19103 Fax: (215) 994-2222 133392.1.07

Form P		Trademark Off	fice Serial No Applicar	Attorney Docket No. BM45413 Serial No.: 10/088,125 Applicant: Thonnard						
Stateme	Information Disclo	osure	Filing Da Art No.		Unknown Unknown					
	(use several Sheets	s if necessary)			Unknown					
(37CFR	1.98(b))									
U.S. PATENT DOCUMENTS										
Exmr Initial	Patent Number	Issue Date	Patentee	Class	Sub- Class	Filing Date If Appropriate				
	5 705 000	2/40/00	B.B. and Thomas			Appropriate				
	5,725,862	3/10/98	Murphy Timothy		- 					
		1				<u> </u>				
		<u> </u>								
			HED FOREIGN PAT	ENT APPLICA	ΓΙΟΝ					
Exmr Initial	Document Number	Publn Date	Country or Pa Office	tent Class	Sub- Class	Translation? Yes No				
	° WO97/13785	17.04.97	WIPO							
	*WO00/78968	28.12.00	WIPO							
		_								
					 					
OTHE	R DOCUMENTS (Includi	ing Author Tit	tle Date Pertinent	Pages Place	of Public:					
		Online, Yoneyı	ma et al., <i>"Pseudo</i>		 	···				
	International Search Report from International Application No. PCT/EP00/09036									
	Murphy et al., "Studies of the outer membrane proteins of <i>Branhamella catarrahlis</i> ", American Journal of Medicine, vol. 88, no. Supp 05A, 14 May 1990, pps 41S-45S									
Examin	er			Date Conside	ered					
	<u></u>			Date Conside	-1 GU					

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449 [6-4])

- * Use publication date indicated on the patent or published application. 37 CFR 1.98(b).
- ** The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.